Stocks · Health care · Biological Products, (No Diagnostic Substances)

Neumora Therapeutics, Inc.

NMRA Clue Score21
United States Fiscal year ends December CIK 0001885522 Results filed 14 Aug 2026

What the insiders did No buying or selling

By person

8 insiders · 0 transactions
16.8×

Paul L. Berns holds 16.8 times base salary in stock. $11.80M of shares against $700.00K in salary for 2025.

Salary from the company's own proxy. The shares are what Paul L. Berns last reported holding, valued at $1.60, the price Common Stock was last bought or sold at on the open market here, on 21 Aug 2026.

Insider
Role
Bought
Sold
Net
Holding
Worth
Change
Paul L Berns
See Remarks
—
—
—
7,395,185
$11.80M
−5.4%
Kristina Burow
Director
—
—
—
6,046,907
$9.65M
+46.4%
ARCH Venture Partners XII, LLC entity
10% owner
—
—
—
6,046,907
$9.65M
+46.4%
ARCH Venture Partners X, LLC entity
10% owner
—
—
—
6,046,907
$9.65M
+46.4%
Robert A. Lenz
Head of R&D
—
—
—
309,092
$493.25K
−1.8%
Joshua Pinto
President & CEO
—
—
—
209,950
$335.04K
−6.3%
Daljit Singh Aurora
See Remarks
—
—
—
48,750
$77.80K
−77.0%
Michael Lee Milligan
See Remarks
—
—
—
21,034
$33.57K
−14.0%

No percentages here. These insiders hold more than one class of share between them, and the share count on file covers one of them rather than all. Dividing the two would compare different things.